Yeah you are probably right, she is most likely out of the loop. Just as long as she can be in the know for the purpose of increasing the DCVAX L manufacturing capacity (thinking Cognate expansion) well in advance of the approval. Wait, how can she out of the loop, but be certain enough about the treatment efficacy to spend millions for manufacturing expansion for...oh never mind :)
I'm also curious what your thoughts are on the plans for the Swaston facility using cells from a patient's "close relative", or from a "stem cell bank from donated umbilical cord blood", and involving "organs from the NHS Blood and Transplant Service that is unsuitable for routine transplantation but can be used as a “scaffold” for product development." Do you think these descriptions match up with the product development for DCVAX L or D? I haven't heard of anything like this in my research of how DCVAX is manufactured. I'm probably missing something very obvious that would explain need for NWBO to integrate this type of cell manufacturing for their DCVAX platform.
News 
Market Data 
Discover 
AI
